Not Yet Recruiting PHASE4 NCT06818773
Inetetamab Plus Chemotherapy ± PD-1/PD-L1 in HER2+ Advanced Biliary Cancer
Efficacy and Safety Study of Inetetamab Combined with Chemotherapy ± PD-1/PD-L1 Inhibitor As First-Line Treatment for HER2-Positive Advanced Biliary Tract Cancer
Sponsor: Eastern Hepatobiliary Surgery Hospital
Conditions
HER2 Positive Metastatic Biliary Tract Cancer
Updated 1 time since 2025 Last updated: Feb 7, 2025 Started: Feb 28, 2025 Primary completion: Dec 31, 2026 Completion: Dec 31, 2027
A PHASE4 clinical study on HER2 Positive and Metastatic Biliary Tract Cancer, this trial is actively recruiting participants. The trial is conducted by Eastern Hepatobiliary Surgery Hospital and has accumulated 1 data snapshot since 2025. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Change History
1 version recorded Not Yet Recruiting — PHASE4
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Eastern Hepatobiliary Surgery Hospital
Data source: Eastern Hepatobiliary Surgery Hospital
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.